Clinical Trial Update: Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the Lung [Phase 2]

View source ↗

Summary

Phase 2 trial updating afatinib in combination with pembrolizumab for non-small cell lung carcinoma (squamous cell) has been completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Carcinoma

Drugs mentioned

• Afatinib (afatinib)
• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: COMPLETED | Results posted: 2021-02-23